HONOLULU (AP) — Pharmaceutical companies have agreed to pay Hawaii $700 million to settle its lawsuit over the efficacy and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Q1 2025 Earnings Call Transcript May 12, 2025 FibroGen, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, ...

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

Ainnocence’s CarbonAI® Platform for AI-Powered Small Molecule Drug Design — Enabling De Novo Generation, Lead Optimization, ...

Welcome to FibroGen first quarter 2025 earnings conference call. (Operator Instructions). Please be advised today's conference is being recorded. I would not like to end the conference over to your ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

Students from Olympia and Ridgeview high schools have graduated from a truck driver training course offered through Heartland Community College to help fill the gap for in-demand jobs.

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

Keith Koffler is the managing editor of The Daily Signal. President Donald Trump says he will announce a new prescription drug initiative he promises will dramatically—and immediately—reduce ...

GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.